Datapoint: Novartis’ Fabhalta Scores First FDA Nod

The FDA on Dec. 6 approved Novartis’ Fabhalta (iptacopan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This is the first FDA approval for the factor B inhibitor, which also has a pending application for immunoglobin A nephropathy. Fabhalta will also be the first oral monotherapy approved to treat PNH, which is typically treated with C5 inhibitors such as Soliris and Ultomiris, both from AstraZeneca. The drugs are administered as injectables or infusions, vs. Fabhalta’s oral route. For the treatment of PNH, Soliris and Ultomiris currently hold covered or better status for 86% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 12/11/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 28

Datapoint: Point32Health Offers In-Home Urgent Care

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Centene Pledges Nearly $1B for Affordable Housing

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today